AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients

• AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC).

• The data showed Lynparza plus abiraterone demonstrated improvement in radiographic progression-free survival (rPFS) versus abiraterone as a 1st-line treatment for mCRPC with or without homologous recombination repair (HRR) gene mutations.

• Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone) is considered standard of care.

• The trial also showed a trend at this interim analysis towards improved overall survival. However, the data are still immature.

• The safety and tolerability were consistent with the known profiles of each medicine.

• The data will be presented at an upcoming medical meeting.

• In July 2017, AstraZeneca and Merck & Co Inc (NYSE: MRK) collaborated to co-develop and co-commercialize Lynparza and Koselugo for multiple cancer types.

• Price Action: AZN stock is up 1.87% at $60.59, and MRK stock is up 1.57% at $74.20 during the premarket session on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• RedHill Settles Movantik Patent Litigation With Aurobindo

• AstraZeneca Invests In Imperial College's Self-Amplifying RNA Tech

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.